{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-005113","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2025-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.160374+00:00","generated_at":"2026-05-23T09:20:22.891277+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MetaVia reports dose-dependent weight loss and no CV effects in Phase 1 MAD study of DA-1726","bullets":["Clear dose-dependent body weight reduction from 8 mg to 32 mg; BMI change significantly greater vs placebo.","No drug-induced heart rate or QTcF increases up to 32 mg at 4 weeks; mean HR decreased in most cohorts.","Previously reported: max weight loss -6.3% and mean -4.3% at Day 26 for 32 mg; fasted glucose lowered -18 mg/dL.","Additional cohorts to determine maximum tolerated dose; 32 mg likely starting dose for future trials.","All pre-funded warrants exercised for 1,430,000 shares post-announcement; no warrants outstanding."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-005113","json":"https://secwatch.observer/filing/0001558370-25-005113.json","markdown":"https://secwatch.observer/filing/0001558370-25-005113.md","text":"https://secwatch.observer/filing/0001558370-25-005113.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000155837025005113/0001558370-25-005113-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000155837025005113/mtva-20250422x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T09:20:22.891277+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}